Endpoints News
Behind Galapagos’ transformation into Lakefront Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T Wed Th F
13 May, 2026
A Better Way to AAV.
Helping you scale your gene therapy with greater efficiency.
sponsored by Forge Biologics
presented by Parexel Biotech
Mov­ing be­yond sci­ence to ac­cess: Solv­ing the ac­cess im­per­a­tive
top stories
1. Post-Hoc: What brought down the FDA commissioner 
2. Behind Galapagos’ transformation into Lakefront Biotherapeutics
3. Tessera says infusion edits 85% of blood cells, pointing to off-the-shelf sickle cell fix
4.
news briefing
Abeona pivots to T cells; AstraZeneca's rare disease drug passes Phase 3
5. Lilly points to low-dose Zepbound and Foundayo as weight loss maintenance options
6. Merck KGaA's clients are stockpiling due to Iran war, supporting guidance boost
7. Iran war disruptions begin to emerge upstream of the pharma supply chain
8. EU reaches provisional deal on Critical Medicines Act
more stories
• 
Karen Weintraub
.

Marty Makary never had a chance to succeed as FDA commissioner, Drew Armstrong writes. Caught between the demands of MAHA, RFK Jr. and Trump, he wasn't a strong or effective enough leader to overcome those forces.
.
Karen Weintraub
Deputy Editor, Endpoints News
Former FDA Commissioner Marty Makary at his Senate confirmation hearing in Washington in 2025 (Bill Clark/CQ Roll Call via AP Images)
1
by Drew Armstrong

Mar­ty Makary nev­er stood a chance.

Over the last few days, the now-for­mer FDA com­mis­sion­er had been left to twist in the wind, af­ter head­lines...

Read full story
Henry Gosebruch, Lakefront Biotherapeutics CEO
2
by Kyle LaHucik

CHICA­GO — From a 22nd-floor of­fice over­look­ing the Chica­go River­walk, in the heart of the Mid­west hub’s white-col­lar down­town dis­trict, Lake­front Bio­ther­a­peu­tics’ ex­ec­u­tives hope to...

Read full story
3
by Ryan Cross

BOSTON —Tessera Ther­a­peu­tics has cre­at­ed an ex­per­i­men­tal gene edit­ing drug for sick­le cell dis­ease that could com­pete with com­mer­cial cell ther­a­pies but is de­liv­ered...

Read full story
DIA 2026 - GLOBAL ANNUAL MEETING
Where regulators and industry align on what's next.
sponsored by DIA
News Briefing: Quick hits from the biopharma web
4
by ENDPOINTS

Plus, news about Am­i­cus Ther­a­peu­tics, Fo­s­un Phar­ma, Du­al­i­ty Bio­ther­a­peu­tics, BioN­Tech and C4 Ther­a­peu­tics.

👁️ Abeona drops eye gene ther­a­pies, piv­ots to sol­id tu­mor T cell...

Read full story
5
by Elizabeth Cairns

Re­duc­ing the dose of Eli Lil­ly’s obe­si­ty shot Zep­bound could pro&